A Pilot Study to Determine the Effects of the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Biomarker; Therapeutic Use
- 30 Mar 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 17 Nov 2015 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017 as reported by ClinicalTrials.gov.
- 12 Nov 2014 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.